Annual report

Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥921.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥613.8bn2020-04-01 → 2021-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥628.9bn2019-04-01 → 2020-03-31dCons.Revenue IFRS (5-year summary)
Operating income¥140.1bn2023-04-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥117.3bn2022-04-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥140.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥97.1bn2020-04-01 → 2021-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥106.5bn2019-04-01 → 2020-03-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥106.4bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥77.3bn2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥85.2bn2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥106.4bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥1.83Tat 2024-03-31Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥1.35Tat 2021-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥1.24Tat 2020-03-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥504.3bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.33Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.33Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥856.7bnat 2021-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥754.8bnat 2020-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥204.9bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥166.9bnat 2020-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥146.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥121.5bn2020-04-01 → 2021-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥117.5bn2019-04-01 → 2020-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥81.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥85.3bn2020-04-01 → 2021-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥84.7bn2019-04-01 → 2020-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥62.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥7.4bn2020-04-01 → 2021-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥14.0bn2019-04-01 → 2020-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥71.52023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥59.52022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥58.722021-04-01 → 2022-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥51.162020-04-01 → 2021-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥56.982019-04-01 → 2020-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥71.472023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥59.482022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.692021-04-01 → 2022-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥51.052020-04-01 → 2021-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥56.312019-04-01 → 2020-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥893.8at 2024-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥746.07at 2023-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥669.23at 2022-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥566.57at 2021-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥501.68at 2020-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio72.5%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio63.4%at 2021-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio60.8%at 2020-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE8.7%2023-04-01 → 2024-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.4%2022-04-01 → 2023-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE9.5%2021-04-01 → 2022-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE9.6%2020-04-01 → 2021-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE11.7%2019-04-01 → 2020-03-31dCons.Rate of return on equity IFRS (5-year summary)
Employees30,591at 2024-03-31Cons.Number of employees
Employees30,207at 2023-03-31Cons.Number of employees
Employees28,294at 2022-03-31dCons.Number of employees
Employees26,482at 2021-03-31dCons.Number of employees
Employees26,438at 2020-03-31dCons.Number of employees
Revenue¥399.8bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥375.0bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥341.4bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥316.4bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥319.0bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Operating income¥77.0bn2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥67.8bn2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥110.7bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥91.1bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥79.4bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥65.3bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥80.1bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥112.0bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥99.7bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥87.9bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥79.0bn2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥62.8bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥52.0bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥65.3bn2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Total assets¥1.44Tat 2024-03-31StandaloneAssets
Total assets¥1.33Tat 2023-03-31StandaloneAssets
Total assets¥1.28Tat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥1.26Tat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥1.15Tat 2020-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥623.6bnat 2024-03-31StandaloneLiabilities
Total liabilities¥566.1bnat 2023-03-31StandaloneLiabilities
Net assets / equity¥813.8bnat 2024-03-31StandaloneNet assets
Net assets / equity¥765.6bnat 2023-03-31StandaloneNet assets
Net assets / equity¥765.4bnat 2022-03-31dStandaloneNet assets
Net assets / equity¥725.2bnat 2021-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥687.2bnat 2020-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥93.8bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥91.5bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥59.052023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥52.612022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥41.522021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥34.442020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥43.652019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥59.032023-04-01 → 2024-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥52.592022-04-01 → 2023-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥41.492021-04-01 → 2022-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥34.372020-04-01 → 2021-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥43.122019-04-01 → 2020-03-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥442023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥402022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥342021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥292020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥282019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥547.68at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥513.67at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥505.54at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥479.13at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥456.22at 2020-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio56.6%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio57.4%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio59.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE11.1%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE10.3%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE8.4%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE7.4%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE10.0%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued745,348,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued747,682,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees5,554at 2024-03-31StandaloneNumber of employees
Employees5,457at 2023-03-31StandaloneNumber of employees
Employees5,377at 2022-03-31dStandaloneNumber of employees
Employees5,247at 2021-03-31dStandaloneNumber of employees
Employees5,087at 2020-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2023-04-01 → 2024-03-31¥4.0bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2024-03-31¥248m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2024-03-31−¥3.2bn
Blood And Cell Technologies Companyreportable segmentcapex2023-04-01 → 2024-03-31¥17.3bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2024-03-316386 pure
Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2024-03-31¥168.3bn
Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2024-03-31¥16.4bn
Cardiac And Vascular Companyreportable segmentcapex2023-04-01 → 2024-03-31¥41.5bn
Cardiac And Vascular Companyreportable segmentemployeesat 2024-03-3116940 pure
Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2024-03-31¥555.7bn
Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2024-03-31¥123.8bn
Medical Care Solutions Companyreportable segmentcapex2023-04-01 → 2024-03-31¥15.6bn
Medical Care Solutions Companyreportable segmentemployeesat 2024-03-316038 pure
Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2024-03-31¥197.6bn
Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2024-03-31¥19.8bn
—segment totalcapex2023-04-01 → 2024-03-31¥74.4bn
—segment totalrevenue external2023-04-01 → 2024-03-31¥921.6bn
—segment totalsegment profit2023-04-01 → 2024-03-31¥160.0bn
Reconciling Itemsreconcilingcapex2022-04-01 → 2023-03-31¥1.5bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2023-03-31¥243m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2023-03-31−¥142m
Blood And Cell Technologies Companyreportable segmentcapex2022-04-01 → 2023-03-31¥21.5bn
Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2023-03-31¥147.6bn
Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2023-03-31¥11.2bn
Cardiac And Vascular Companyreportable segmentcapex2022-04-01 → 2023-03-31¥31.9bn
Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2023-03-31¥480.6bn
Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2023-03-31¥112.2bn
Medical Care Solutions Companyreportable segmentcapex2022-04-01 → 2023-03-31¥20.9bn
Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2023-03-31¥191.7bn
Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2023-03-31¥14.8bn
—segment totalcapex2022-04-01 → 2023-03-31¥74.3bn
—segment totalrevenue external2022-04-01 → 2023-03-31¥820.0bn
—segment totalsegment profit2022-04-01 → 2023-03-31¥138.2bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2024-03-31260 pure
Cardiac And Vascular Companyreportable segmentemployeesat 2024-03-311893 pure
Medical Care Solutions Companyreportable segmentemployeesat 2024-03-312332 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,828
ItemContextValueUnit
Finance income IFRSPrior1YearDuration2649000000JPY
Finance income IFRSCurrentYearDuration3529000000JPY
Financial liabilities measured at amortized cost interest expenses IFRSPrior1YearDuration1453000000JPY
Financial liabilities measured at amortized cost interest expenses IFRSCurrentYearDuration1355000000JPY
Lease obligations interest expenses IFRSPrior1YearDuration777000000JPY
Lease obligations interest expenses IFRSCurrentYearDuration710000000JPY
Foreign exchange loss IFRSPrior1YearDuration1741000000JPY
Foreign exchange loss IFRSCurrentYearDuration586000000JPY
Change in fair value of contingent considerations expense IFRSPrior1YearDuration44000000JPY
Change in fair value of contingent considerations expense IFRSCurrentYearDuration123000000JPY
Finance costs IFRSPrior1YearDuration4016000000JPY
Finance costs IFRSCurrentYearDuration2775000000JPY
Cash and depositsPrior1YearInstant_NonConsolidatedMember91483000000JPY
Cash and depositsCurrentYearInstant_NonConsolidatedMember93765000000JPY
Notes receivable tradePrior1YearInstant_NonConsolidatedMember85000000JPY
Notes receivable tradeCurrentYearInstant_NonConsolidatedMember96000000JPY
Accounts receivable tradePrior1YearInstant_NonConsolidatedMember108385000000JPY
Accounts receivable tradeCurrentYearInstant_NonConsolidatedMember123838000000JPY
Merchandise and finished goodsPrior1YearInstant_NonConsolidatedMember50166000000JPY
Merchandise and finished goodsCurrentYearInstant_NonConsolidatedMember56494000000JPY
Work in processPrior1YearInstant_NonConsolidatedMember13101000000JPY
Work in processCurrentYearInstant_NonConsolidatedMember14433000000JPY
Raw materials and suppliesPrior1YearInstant_NonConsolidatedMember15261000000JPY
Raw materials and suppliesCurrentYearInstant_NonConsolidatedMember17722000000JPY
Prepaid expensesPrior1YearInstant_NonConsolidatedMember3395000000JPY
Prepaid expensesCurrentYearInstant_NonConsolidatedMember3752000000JPY
Short term loans receivablePrior1YearInstant_NonConsolidatedMember74455000000JPY
Short term loans receivableCurrentYearInstant_NonConsolidatedMember87330000000JPY
Other caPrior1YearInstant_NonConsolidatedMember19996000000JPY
Other caCurrentYearInstant_NonConsolidatedMember22304000000JPY
Allowance for doubtful accounts caPrior1YearInstant_NonConsolidatedMember-519000000JPY
Allowance for doubtful accounts caCurrentYearInstant_NonConsolidatedMember-568000000JPY
Current assetsPrior1YearInstant_NonConsolidatedMember375812000000JPY
Current assetsCurrentYearInstant_NonConsolidatedMember419170000000JPY
Buildings netPrior1YearInstant_NonConsolidatedMember34644000000JPY
Buildings netCurrentYearInstant_NonConsolidatedMember33430000000JPY
Structures netPrior1YearInstant_NonConsolidatedMember1524000000JPY
Structures netCurrentYearInstant_NonConsolidatedMember1581000000JPY
Machinery and equipment netPrior1YearInstant_NonConsolidatedMember22914000000JPY
Machinery and equipment netCurrentYearInstant_NonConsolidatedMember20990000000JPY
Vehicles netPrior1YearInstant_NonConsolidatedMember84000000JPY
Vehicles netCurrentYearInstant_NonConsolidatedMember83000000JPY
Tools furniture and fixtures netPrior1YearInstant_NonConsolidatedMember8267000000JPY
Tools furniture and fixtures netCurrentYearInstant_NonConsolidatedMember7783000000JPY
LandPrior1YearInstant_NonConsolidatedMember18664000000JPY
LandCurrentYearInstant_NonConsolidatedMember18664000000JPY
Lease assets net ppePrior1YearInstant_NonConsolidatedMember212000000JPY
Lease assets net ppeCurrentYearInstant_NonConsolidatedMember126000000JPY
Construction in progressPrior1YearInstant_NonConsolidatedMember14383000000JPY
Construction in progressCurrentYearInstant_NonConsolidatedMember26227000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identitynon_consolidated 2023-03-31pass rounding
balance sheet identitynon_consolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass